{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:09:40Z","timestamp":1790186980074,"version":"4.1.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1097\/wnf.0b013e318279bcfa","type":"journal-article","created":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T10:15:50Z","timestamp":1358417750000},"page":"8-13","source":"Crossref","is-referenced-by-count":46,"title":["Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease"],"prefix":"10.1097","volume":"36","author":[{"given":"Aaron H.","family":"Burstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scot","family":"Styren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaren W.","family":"Landen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy W.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"McCush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Alvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Kupiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Bednar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210203","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimers disease: the amyloid cascade hypothesis.","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":". Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease.","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1212\/WNL.0b013e3181c918b5","article-title":". Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.","volume":"74","author":"Bourgeat","year":"2010","journal-title":"Neurology"},{"key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","article-title":". Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimers disease.","volume":"46","author":"McLean","year":"1999","journal-title":"Ann Neurol"},{"key":"R6-3-20210203","first-page":"566","article-title":"Anti-amyloid antibody drugs in clinical testing for Alzheimers disease.","volume":"12","author":"Bednar","year":"2009","journal-title":"IDrugs"},{"key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":". Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimers disease.","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"14657","DOI":"10.1073\/pnas.0404866101","article-title":". Immunotherapy for Alzheimers disease.","volume":"101","author":"Gelinas","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-2094-3-11","article-title":". Intracranial administration of deglycosylated C-terminal-specific anti-A antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice.","volume":"3","author":"Carty","year":"2006","journal-title":"J Neuroinflammation"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1523\/JNEUROSCI.0695-06.2006","article-title":". Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice.","volume":"26","author":"Wilcock","year":"2006","journal-title":"J Neurosci"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000264823","article-title":". Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies.","volume":"34","author":"Fredrickson","year":"2010","journal-title":"Neuroepidemiology"},{"key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":". Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/WNF.0b013e3181cb577a","article-title":". Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.","volume":"33","author":"Siemers","year":"2010","journal-title":"Clin Neuropharmacol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-201301000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:52:58Z","timestamp":1618278778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201301000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318279bcfa","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}